ES8401486A1
(es)
|
1981-11-10 |
1983-12-01 |
Wellcome Found |
Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
|
US4847256A
(en)
|
1986-10-16 |
1989-07-11 |
American Cyanamid Company |
4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
|
AU650953B2
(en)
|
1991-03-21 |
1994-07-07 |
Novartis Ag |
Inhaler
|
US5728536A
(en)
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
US6136595A
(en)
|
1993-07-29 |
2000-10-24 |
St. Jude Children's Research Hospital |
Jak kinases and regulations of cytokine signal transduction
|
US5543523A
(en)
|
1994-11-15 |
1996-08-06 |
Regents Of The University Of Minnesota |
Method and intermediates for the synthesis of korupensamines
|
US5705625A
(en)
|
1994-12-15 |
1998-01-06 |
The Johns Hopkins University School Of Medicine |
Nucleic Acid Encoding novel protein tyrosine kinase
|
US7070972B1
(en)
|
1995-01-13 |
2006-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Janus family kinases and identification of immune modulators
|
EP0842195A1
(en)
|
1995-07-06 |
1998-05-20 |
Zeneca Limited |
Peptide inhibitors of fibronectine
|
US6248713B1
(en)
|
1995-07-11 |
2001-06-19 |
Biogen, Inc. |
Cell adhesion inhibitors
|
US7091020B1
(en)
|
1995-12-05 |
2006-08-15 |
Incyte Corporation |
Human Jak2 kinase
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
US6235741B1
(en)
|
1997-05-30 |
2001-05-22 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
FR2791562B1
(fr)
|
1999-03-29 |
2004-03-05 |
Oreal |
Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
|
YU25500A
(sh)
|
1999-05-11 |
2003-08-29 |
Pfizer Products Inc. |
Postupak za sintezu analoga nukleozida
|
CA2376835C
(en)
|
1999-07-02 |
2009-09-15 |
Eisai Co., Ltd. |
Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
|
PT1382339E
(pt)
|
1999-12-10 |
2008-02-06 |
Pfizer Prod Inc |
Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
|
GB0028383D0
(en)
|
2000-11-21 |
2001-01-03 |
Novartis Ag |
Organic compounds
|
EP1241176A1
(en)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Purine derivatives for the treatment of ischemia
|
WO2003053930A1
(en)
|
2001-12-20 |
2003-07-03 |
Bayer Healthcare Ag |
1,4-dihydro-1,4-diphenylpyridine derivatives
|
KR20040097375A
(ko)
|
2002-04-23 |
2004-11-17 |
시오노기 앤드 컴파니, 리미티드 |
피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
|
US7161003B1
(en)
|
2002-09-04 |
2007-01-09 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US7129239B2
(en)
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
US7199119B2
(en)
|
2002-10-31 |
2007-04-03 |
Amgen Inc. |
Antiinflammation agents
|
AU2003299651A1
(en)
|
2002-12-11 |
2004-06-30 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
EP1615697A2
(en)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
|
US20070270408A1
(en)
|
2003-04-11 |
2007-11-22 |
Novo Nordisk A/S |
Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
|
WO2004089416A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
|
JP2006522744A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
|
US7393873B2
(en)
|
2003-07-02 |
2008-07-01 |
Merck & Co., Inc. |
Arylsulfonamide derivatives
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
SE0302487D0
(sv)
|
2003-09-18 |
2003-09-18 |
Astrazeneca Ab |
Novel compounds
|
GB0329214D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Novel compounds
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
CA2563305A1
(en)
|
2004-04-09 |
2005-11-24 |
University Of South Florida |
Combination therapies for cancer and proliferative angiopathies
|
CA2565037A1
(en)
|
2004-04-28 |
2005-11-10 |
Cv Therapeutics, Inc. |
Purine derivatives as a1 adenosine receptor antagonists
|
JP2008504294A
(ja)
|
2004-06-25 |
2008-02-14 |
アムジエン・インコーポレーテツド |
サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
|
PT1812440E
(pt)
|
2004-11-04 |
2011-01-25 |
Vertex Pharma |
Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
|
GB0502258D0
(en)
|
2005-02-03 |
2005-03-09 |
Argenta Discovery Ltd |
Compounds and their use
|
WO2007013673A1
(en)
|
2005-07-29 |
2007-02-01 |
Astellas Pharma Inc. |
Fused heterocycles as lck inhibitors
|
WO2007039797A1
(en)
|
2005-10-03 |
2007-04-12 |
Pfizer Products Inc. |
Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
|
AR057979A1
(es)
|
2005-10-06 |
2008-01-09 |
Schering Corp |
PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
|
KR20080063806A
(ko)
*
|
2005-10-06 |
2008-07-07 |
쉐링 코포레이션 |
단백질 키나제 억제제로서의 피라졸로피리미딘
|
ATE517874T1
(de)
|
2005-10-21 |
2011-08-15 |
Exelixis Inc |
Pyrimidinone als modulatoren von caseinkinase ii (ck2)
|
BRPI0619517A2
(pt)
|
2005-12-08 |
2011-10-04 |
Novartis Ag |
ácidos pirazolo[1,5-a]piridina-3-carboxìlicos como inibidores de ephb e vegfr2 cinase
|
US8541406B2
(en)
|
2006-02-07 |
2013-09-24 |
Nv Remynd |
Thiadiazole derivatives for the treatment of neurodegenerative diseases
|
TW200800997A
(en)
|
2006-03-22 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
AR061793A1
(es)
|
2006-07-05 |
2008-09-24 |
Mitsubishi Tanabe Pharma Corp |
Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
CN101522682A
(zh)
|
2006-10-30 |
2009-09-02 |
诺瓦提斯公司 |
作为抗炎剂的杂环化合物
|
US20080176870A1
(en)
|
2006-11-20 |
2008-07-24 |
Bert Nolte |
Heterobicyclic metalloprotease inhibitors
|
WO2009017954A1
(en)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibitors of jak2 kinase
|
BRPI0818543A2
(pt)
|
2007-10-12 |
2018-10-23 |
Ingenium Pharmaceuticals Gmbh |
inibidores de proteína cinase
|
ES2610190T3
(es)
|
2007-11-28 |
2017-04-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
|
AU2008345225A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
MX2010014005A
(es)
|
2008-06-20 |
2011-02-15 |
Genentech Inc |
Compuestos de triazolopiridina inhibidores de jak y los metodos.
|
WO2010019762A1
(en)
|
2008-08-13 |
2010-02-18 |
Jenrin Discovery |
Purine compounds as cannabinoid receptor blockers
|
CA2740792C
(en)
|
2008-10-31 |
2016-06-21 |
Genentech, Inc. |
Pyrazolopyrimidine jak inhibitor compounds and methods
|
WO2010063487A1
(en)
|
2008-12-05 |
2010-06-10 |
Merz Pharma Gmbh & Co. Kgaa |
Pyrazolopyrimidines, a process for their preparation and their use as medicine
|
BRPI1008473A2
(pt)
|
2009-02-06 |
2019-04-02 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
|
TWI461425B
(zh)
|
2009-02-19 |
2014-11-21 |
Janssen Pharmaceuticals Inc |
作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
|
UA110324C2
(en)
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Jak inhibitory compounds based on pyrazolo pyrimidine
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
AU2010309882B2
(en)
|
2009-10-20 |
2016-01-28 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
|
CA2793024A1
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
WO2011134831A1
(en)
|
2010-04-30 |
2011-11-03 |
Cellzome Limited |
Pyrazole compounds as jak inhibitors
|
CN105367577B
(zh)
|
2010-07-13 |
2019-04-23 |
弗·哈夫曼-拉罗切有限公司 |
作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
|
WO2012075393A2
(en)
|
2010-12-02 |
2012-06-07 |
President And Fellows Of Harvard College |
Activators of proteasomal degradation and uses thereof
|
US9169260B2
(en)
*
|
2011-03-22 |
2015-10-27 |
Merck Sharp & Dohme Corp. |
Amidopyrazole inhibitors of interleukin receptor-associated kinases
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
US9428511B2
(en)
|
2012-09-06 |
2016-08-30 |
Bristol-Myers Squibb Company |
Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
|
US9409893B2
(en)
|
2012-11-09 |
2016-08-09 |
Jacobus Pharmaceutical Company, Inc. |
Heteroaryl derivatives and uses thereof
|
EP3019171B1
(en)
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
CA2929316C
(en)
|
2013-11-08 |
2021-12-28 |
Takeda Pharmaceutical Company Limited |
Pyrazole for the treatment autoimmune disorders
|
WO2015073267A1
(en)
|
2013-11-15 |
2015-05-21 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
JP2017516850A
(ja)
*
|
2014-05-23 |
2017-06-22 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Jak阻害剤である5−クロロ−2−ジフルオロメトキシフェニルピラゾロピリミジン化合物
|
RU2707076C2
(ru)
|
2014-05-23 |
2019-11-22 |
Файбро Энимал Хэлс Корпорейшн |
Комбинация, композиция и способ введения комбинации или композиции животным
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
JP6734860B2
(ja)
|
2014-11-06 |
2020-08-05 |
リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. |
置換ピラゾロ[1,5−a]ピリミジンおよび医療疾患の治療におけるその使用
|
EP3268004B1
(en)
|
2015-03-12 |
2019-12-18 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
EP3267996B1
(en)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
US10329295B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of IRAK4 activity
|
TW201720828A
(zh)
|
2015-11-23 |
2017-06-16 |
赫孚孟拉羅股份公司 |
治療性化合物及組合物以及其使用方法
|
CN108473501B
(zh)
|
2016-02-18 |
2021-07-16 |
豪夫迈·罗氏有限公司 |
治疗化合物、其组合物及使用方法
|
JP6900491B2
(ja)
|
2016-12-29 |
2021-07-07 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ピラゾロピリミジン化合物及びその使用方法
|
CN110494434B
(zh)
|
2017-03-14 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
吡唑并氯苯基化合物、其组合物及其使用方法
|
KR20200010390A
(ko)
*
|
2017-05-22 |
2020-01-30 |
에프. 호프만-라 로슈 아게 |
치료 화합물 및 조성물, 및 이의 사용 방법
|
CN110678467B
(zh)
|
2017-05-22 |
2023-06-13 |
豪夫迈·罗氏有限公司 |
治疗化合物和组合物及其使用方法
|